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Diffuse large B-cell lymphoma (DLBCL) is characterized by extensive
genetic heterogeneity, and this results in unpredictable responses to the cur-
rent treatment, R-CHOP, which consists of a cancer drug combination
supplemented with the humanized CD20-targeting monoclonal antibody
rituximab. Despite improvements in the patient response rate through
rituximab addition to the treatment plan, up to 40% of DLBCL patients
end in a relapsed or refractory state due to inherent or acquired resistance
to the regimen. Here, we employ a lentiviral genome-wide clustered regu-
larly interspaced short palindromic repeats library screening approach to
identify genes involved in facilitating the rituximab response in cancerous
B cells. Along with the CD20-encoding MS4A1 gene, we identify genes
related to B-cell receptor (BCR) signaling as mediators of the intracellular
signaling response to rituximab. More specifically, the B-cell linker protein
(BLNK) and Bruton’s tyrosine kinase (BTK) genes stand out as pivotal
genes in facilitating direct rituximab-induced apoptosis through mecha-
nisms that occur alongside complement-dependent cytotoxicity (CDC). Our
findings demonstrate that rituximab triggers BCR signaling in a BLNK-
and BTK-dependent manner and support the existing notion that inter-
twined CD20 and BCR signaling pathways in germinal center B-cell-like-
subtype DLBCL lead to programmed cell death.
1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the pre-
dominant subtype of non-Hodgkin lymphomas (NHL)
accounting for around 30% of NHL cases [1]. DLBCL
is characterized by extensive genetic and molecular
heterogeneity, which results in unpredictable and vary-
ing responses to treatment [2–5]. DLBCL subclasses
have been distinguished by microarray-based gene
expression profiling and divided into activated B-cell-
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like (ABC) and germinal center B-cell-like (GCB) [6].
This classification reflects the cell of origin and distin-
guishes the two subclasses of DLBCL with regard to
genetic alterations, oncogenic mechanisms, and clinical
outcome [7,5]. Recently, next-generation sequencing
(NGS) methods have confirmed the molecular subclas-
sification and further contributed to the exploration of
DLBCL heterogeneity, unveiling new details on genetic
drivers, differences between ABC and GCB subclasses,
and their impact on clinical outcome [2–4].
R-CHOP, a cocktail of drugs consisting of ritux-
imab (R), cyclophosphamide (C), doxorubicin (H),
vincristine (O), and prednisone (P), constitutes the
current standard regimen for the treatment of
DLBCL. Supplementing CHOP with rituximab
(RTX) has improved the response rate from 63% to
76% [8,9], but 30–35% of patients progress to relapse
or refractory disease and eventually succumb [10].
Stratification by ABC or GCB subclass differentiates
the R-CHOP response, with the 5-year overall sur-
vival for GCB being 69  3% compared to 53  3%
for patients with ABC-type DLBCL [5]. RTX is a
chimeric monoclonal antibody targeting CD20, a pro-
tein expressed and presented on the surface of B cells
through various developmental stages [11]. Binding of
RTX to CD20 induces complement-dependent cyto-
toxicity (CDC) via the classic pathway [12] and/or
recruitment of immune effector cells, leading to anti-
body-dependent cellular cytotoxicity [13,14]. More-
over, recognition of CD20 by RTX leads to the
aggregation in lipid rafts [15], which initiates a cas-
cade of intracellular signaling events involving cal-
cium influx [16,17] and phosphorylation by SRC
family kinases [18,19], leading to apoptosis and/or cell
cycle arrest [18,20–22].
Clustered regularly interspaced short palindromic
repeats (CRISPR), part of the adaptive immune sys-
tem in bacteria [23], has emerged as a powerful tool
for introduction of knockout (KO) mutations in prede-
termined genomic loci in eukaryotic cells [24]. CRISPR
action is based on single-guide RNA (sgRNA)-guided
recruitment of Cas9 endonuclease to a genomic locus,
leading to formation of a targeted double-stranded
DNA break [25] and insertion or deletion of one or
more base pairs after repair by nonhomologous end
joining. CRISPR-based gene KO is the hallmark of
genome-wide screening technologies based on lentiviral
delivery of sgRNAs targeting all genes, allowing iden-
tification of genes affecting a specific cellular pheno-
type of interest. CRISPR screens have successfully
identified genes driving cell proliferation and tumor
growth in various cancers [26,27] and were utilized to
characterize functional drivers and unravel interactions
of ibrutinib in DLBCL [3,28]. Here, we exploit the
power of genome-wide CRISPR screens to identify
genes affecting the resistance of cancerous B cells to
RTX via complement-dependent mechanisms and
direct depletion. Our studies reveal that KO mutations
in only one single gene, the MS4A1 gene encoding
CD20, are able to rescue cell depletion induced by
CDC. Furthermore, our findings support a central role
of B-cell receptor (BCR) signaling in facilitating direct
RTX-induced apoptosis in the absence of CDC and
point to the Bruton’s tyrosine kinase (BTK) and B-cell
linker protein (BLNK) proteins as key mediators of
sensitivity to direct RTX-induced cell depletion in
GCB-DLBCL.
2. Materials and methods
2.1. Cell lines
HEK293T and the DLBCL cell lines OCI-Ly-7, SU-
DHL-5, and RIVA were maintained as previously
described [29].
2.2. Plasmid construction
pLentiCRISPR v2 (Addgene plasmid # 52961; http://
n2t.net/addgene:52961; RRID:Addgene_52961) [30]
and pLentiCas9-Blast (Addgene plasmid # 52962;
http://n2t.net/addgene:52962; RRID:Addgene_52962)
[30] were kindly provided by Feng Zhang. pLX_311-
KRAB-dCas9 was a gift from John Doench, William
Hahn, and David Root (Addgene plasmid # 96918;
http://n2t.net/addgene:96918; RRID:Addgene_96918)
[31]. plentiCRISPR V2 Ctrl sgRNA was generated pre-
viously [29]. pCCL/PGK-eGFP has been described
previously [32]. sgRNA design was performed using
GPP sgRNA designer from Broad Institute [33,34], or
sgRNA sequences were derived from either Human
GeCKOv2 CRISPR KO pooled library or Human
Brunello CRISPR KO pooled library and are available
in Appendix S1. Cloning of sgRNAs into different
backbones was performed as described in Ref. [35],
but using Esp3I. All restriction enzymes were pur-
chased from Thermo Fisher Scientific, Waltham, MA,
USA. plentiGuide-Puro was cloned by digesting plenti-
Guide-Puro Gecko library part A with SmaI and
NdeI. The sgRNA scaffold was amplified from pLenti-
CRISPR v2 and part of U6 amplified from pLenti-
Guide-Puro Gecko library part A. Fragments were
assembled using NEBuilder HiFi DNA Assembly
Master Mix (New England Biolabs, Ipswich, MA,
USA). pCCL/PGK-MS4A1 was cloned by digesting
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pCCL/PGK-eGFP with BoxI and XhoI. To introduce
silent mutations in the MS4A1 sgRNA 1 binding site,
MS4A1 cDNA was amplified in three separate reac-
tions, introducing silent mutations in the overlapping
regions. Fragments were assembled using NEBuilder
HiFi DNA Assembly Master Mix.
2.3. Lentiviral vector production and titration
Lentiviral production was performed in HEK293T
cells as previously described [36]. Titration in OCI-Ly-
7 was performed by quantification of proviral elements
in genomic DNA as previously described. Transduc-
tions were performed without any additives in stan-
dard culture medium.
2.4. Genome-wide CRISPR screening
OCI-Ly-7 cells were screened using the GeCKOv2 gen-
ome-wide library, essentially as previously described
[37], at three different conditions: (a) medium contain-
ing human serum (HS; mock), (b) medium containing
10 µgmL1 RTX (MabThera; Roche, Copenhagen,
Denmark), one-time administration of HS [exposure to
CDC conditions, SEC (RTX-SEC); 14 days], and (c)
medium with 10 µgmL1 RTX increased to
25 µgmL1 at day 16 and with repeated re-adminis-
tration of HS [repeated exposure to CDC conditions,
REC (RTX-REC); 21 days].
Human GeCKOv2 CRISPR KO pooled library was
a gift from Feng Zhang (Addgene #1000000049,
Watertown, MA, USA). After plasmid amplification
of the library as described previously [37], intact
sgRNA representation was validated by targeted
NGS. Sequencing detected 99.98% of the 123 411
sgRNAs contained in the Gecko v2 library in our
plasmid pool, and all protein-encoding genes were still
targeted by at least five sgRNAs. Furthermore,
98.23% of sgRNAs were covered by 20 reads or more.
After lentiviral preparation of the library, screening
was initiated at 1000 copies per sgRNA, following
transduction [transduced at 0.5 multiplicity of infec-
tion (MOI); titer estimation in Fig. S2A]. Throughout
the duration of the screen, a library coverage of 1000
copies pr. sgRNA was maintained when passaging
cells. A minimum of 1.25 9 108 cells were harvested
per sample, and genomic DNA was purified. PCR
preparations for sequencing were carried out by a
nested PCR approach. The first PCR was run on
256 lg gDNA to cover the representation of sgRNAs
at 500 copies at 20 cycles. Using 50-TGTGGAAA
GGACGAAACACC-30 (forward) and 50-
GTTTGTATGTCTGTTGCTAT-30 (reverse), thirteen
individual PCR two reactions were run at 18 cycles,
and the resulting 250 bp PCR amplicon was run on a
gel and purified by gel extraction. Next-generation
amplicon sequencing was carried out at BGI-Research,
Shenzhen. Briefly, PCR amplicons were processed by
end repair and ligated to BGISEQ sequencer compati-
ble adapters, generating DNB-based sequencing
libraries without PCR amplification. The quality and
quantity of the sequencing libraries were assessed
using Agilent 2100 BioAnalyzer (Agilent Technologies,
Santa Clara, CA, USA). Finally, the libraries were
sequenced on the BGISEQ-500 (MGI Tech., Shen-
zhen, China) with 50 paired-end read (PE50). Map-
ping of sgRNA reads was performed by MAGeCK
version 0.5.8 count with default parameters, following
mapping sample coverage ranging from 106 to 218.
After the mapping of sgRNAs, sgRNAs targeting
microRNA-encoding genes were filtered out to focus
on protein-encoding genes. Analysis was performed
with MAGeCK version 0.5.8 test function using
default parameters and the built-in control sgRNAs
from the Gecko v2 library. The sequencing data from
our genome-wide CRISPR screen are available at
NCBI gene expression omnibus, under accession num-
ber GSE139385.
2.5. Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed
using Enrichr [38,39]. A weighted value for each gene
was calculated by subtracting the false discovery rate
(FDR) value from 1. The genes submitted to Enrichr,
the resulting top five pathways from five different
databases, and the different databases used to compile
the set of BCR-related genes are available from
Appendix S2.
2.6. Rituximab cell viability assay
All assays were performed with 20% serum added.
Assays with heat-inactivated Pooled Normal Human
Male AB Serum (Innovative Research, Novy, MI,
USA) had 50 µgmL1 RTX (MabThera; Roche) in
1 mL total; HS was heat-inactivated at 56 °C for
30 min. Assays with active HS had 10 µgmL1 RTX.
In all assays, saline controls were included. For assays
spanning 24 and 48 h, 3 9 105 cells were seeded,
whereas 1.5 9 105 cells were seeded in 72-h assays.
Following treatment, living cells were counted using
trypan blue exclusion, using a Neubauer chamber
(0.0025 mm2). Saline-treated populations were
included to account for population-specific growth rate
in the absence of RTX.
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2.7. Apoptosis assay
Following treatment with RTX, apoptosis levels in
each population were determined by annexin staining
and quantified by flow cytometry.
2.8. Flow cytometry
Levels of RTX-induced apoptosis were measured as
follows. Following treatment, cells were washed with
PBS + 1%BSA and stained first with LIVE/DEADTM
Fixable Near-IR Stain (Thermo Fisher Scientific, Wal-
tham, MA, USA) 1 : 1000 in 100 µL for 30 min. at
4 °C. After washing cells in Annexin V binding buffer
(cat. 556454, ABB; BD PharmingenTM, Franklin Lakes,
NJ, USA) + 1% BSA, cells were stained with 5 µL
PE-conjugated Annexin V (cat. 556422; BD Pharmin-
genTM) in a total of 100 µL for 15 min at room tem-
perature. Cells were subsequently washed and fixated
in ABB + 1% formaldehyde. Lastly, cells were washed
and resuspended in ABB + 1% BSA. Apoptotic levels
were quantified on a NovoCyte Flow Cytometer
immediately after preparation. Quantification of sur-
face CD20 levels was performed as follows. Cells were
washed with PBS + 1% BSA and stained first with
either LIVE/DEADTM Fixable Near-IR or LIVE/
DEADTM Fixable Violet Stain (Thermo Fisher Scien-
tific) 1 : 1000 in 100 µL for 30 min at 4 °C. After
washing the cells, they were stained with APC-conju-
gated anti-CD20 (cat. 55976; BD PharmingenTM),
15 µL in 100 µL for 30 min at 4 °C. Cells were
subsequently washed and fixated in PBS + 1%
formaldehyde. Lastly, cells were washed and resus-
pended in ABB + 1% BSA. Fluorescence was quanti-
fied on a NovoCyte Flow Cytometer (ACEA
Biosciences, San Diego, CA, USA) or a LSRFortessa
analyzer (BD Biosciences, Franklin Lakes, NJ, USA).
For all stains, fluorescence minus one stains were also
included.
2.9. Quantification of mRNA levels by RT-qPCR
Cells were washed in PBS, and total RNA was isolated
using chloroform and TRIzol reagent (Thermo
Fisher Scientific). For each sample, 5–10 9 106 cells
were harvested and lysed in 1 mL TRIzol; following
the first chloroform separation (100 µL), a second sep-
aration with 300 µL of chloroform was performed.
Total RNA was precipitated with isopropanol over-
night at 80 °C, and the resulting pellet was washed
in 70% ethanol and resuspended in 50–100 µL. All
samples were at all times stored at 80 °C. Total
RNA was treated with DNAse I (Thermo Fisher
Scientific). First-strand cDNA synthesis was performed
using Maxima First Strand cDNA Synthesis for qPCR
(Thermo Fisher Scientific) according to the manufac-
turer’s protocol. Maxima Probe qPCR Master Mix
(29; Thermo Fisher Scientific) was used for reactions
of 15 µL total. TaqMan Assay primer-probe set for
MS4A1 (Hs0544819_m1) was used to detect MS4A1
mRNA levels. RPLP0 primers and probe sequences
are available in Appendix S2. Reported MS4A1 Ct
values are all relative to RPLP0, and the displayed val-
ues have been normalized to na€ıve cells.
2.10. Indel detection
The ‘indel rate’ for a cell population indicates the per-
centage of targeted alleles in the population carrying
an insertion or a deletion potentially leading to gene
KO. Indel rates as a measure of CRISPR-directed KO
efficiency were quantified by TIDE analysis. Primer
and sgRNA sequences used for TIDE analysis are
available in Appendix S2.
2.11. Western blot
Cells were counted, and 1 9 106 cells were pelleted
and washed twice in PBS. Cells were lysed in Pierce
RIPA buffer (Thermo Fisher Scientific) with Roche
Complete ULTRA Tablets protease inhibitor 91 and
10 mM Naf. A total of 50 µL lysis buffer was used to
1 9 106 cells, following incubation of the samples for
15 min on ice. Samples were then sonicated for 6 min
corresponding to six cycles of 30 s on and 30 s off.
After sonication, cell debris was pelleted by centrifuga-
tion at 14 000 g for 15 min. XT sample buffer 4X and
DTT (Bio-Rad, Hercules, CA, USA) were added, and
samples were then incubated at 100 °C for 5 min.
Equal volumes of each sample were loaded. Samples
were separated on Criterion TGX Precast 18 well gels
10% (Bio-Rad) in MOPS SDS Running Buffer
(Thermo Fisher Scientific). The Precision Plus Pro-
teinTM All Blue Prestained Protein Standards (Bio-Rad)
ladder was loaded for size determination. Protein was
transferred to Trans-Blot TurboTM Mini PVDF mem-
branes and blocked in washing buffer (TBS with
0.05% Tween-20) with 5% skimmed milk. Primary
antibodies were incubated overnight at 4 °C. BLNK
was detected using BLNK(2B11) mouse monoclonal
antibody (Santa Cruz Biotechnology, Dallas, TX
USA) diluted 1 : 1000, BTK was detected using BTK
(D3H5) rabbit monoclonal antibody (Cell Signaling
and Technology) diluted 1 : 1000, and Vinculin was
detected using Vinculin (V9131) mouse monoclonal
antibody (Sigma-Aldrich, St. Louis, MO, USA) diluted
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1 : 10 000. After washing on the following day, mem-
branes were incubated with secondary antibody HRP-
conjugated anti-rabbit (P0448) or HRP-conjugated
anti-mouse (P0447; Agilent Technologies). Membranes
were visualized using Clarity Western ECL Substrate
(Bio-Rad). Uncropped western blot pictures are
included in Figs S1–S11.
2.12. Figures and layout
Plots and graphs were created using either GRAPHPAD
PRISM (GraphPad Software, San Diego, CA, USA)
8.0.2 or with R 3.5.1 (packages: ggplot2, gplots) lay-
out, and final setup was done using Adobe Illustrator
CC 2017 (Adobe, San Jose, CA, USA).
2.13. Statistical analysis
Statistical evaluation of library screen data was per-
formed by MAGeCK as previously described [40]. Cal-
culations from GSEA were performed by Enrichr as
previously described [38,39]. Experimental data were
analyzed using GRAPHPAD PRISM 8.0.2. To determine
statistical values in each experiment, Dunnett’s multi-
ple comparison test was performed. In each case, the
multiple comparison test was carried out using the des-
ignated control sample from each experiment as con-
trol. The P-values reported by Dunnett’s multiple
comparison test are multiplicity-adjusted P-values and
not exact P-values.
3. Results
3.1. Resistance of OCI-Ly-7 B cells harboring
biallelic MS4A1 knockout mutations in the
presence and absence of active human serum
To identify genes modulating the response of B cells to
RTX, we set out to perform an unbiased genome-wide
CRISPR screen in OCI-Ly-7, a GCB-subtype DLBCL
cell line, using the Gecko v2 lentiviral library [30] con-
sisting of 123 411 unique sgRNAs. It was initially vali-
dated that lentiviral vectors facilitate effective transfer
of the CRISPR system to GCB-subtype DLBCL cell
lines (Fig. S1) and that endogenous CD20 expression
was unaffected by this transfer method (Fig. S2). We
then generated a OCI-Ly-7-Cas9 clone stably express-
ing Streptococcus pyogenes Cas9 (SpCas9; Fig. 1A)
and confirmed SpCas9 activity by lentiviral delivery of
sgRNA targeting the MS4A1 gene encoding CD20,
leading to an indel rate of 85% (Fig. 1B) and strongly
reduced CD20 expression (Fig. 1C). In the presence of
HS providing human complement, OCI-Ly-7-Cas9
cells carrying MS4A1 KO mutations (OCI-Ly-7/
MS4A1-KO) were resistant to RTX, whereas na€ıve
cells were drastically depleted primarily due to CDC
(Fig. 1D). Also, na€ıve OCI-Ly-7-Cas9 cells or cells sta-
bly expressing control sgRNA were sensitive to the
direct effect of RTX in the presence of heat-inactivated
HS (HIHS), although the effect was less dramatic
compared to conditions supporting CDC (Fig. 1D).
Notably, OCI-Ly-7/MS4A1-KO cells cultured in HIHS
were resistant to RTX treatment. Collectively, these
studies showed potent CRISPR-directed KO in OCI-
Ly-7-Cas9 cells and confirmed the emergence of resis-
tance to RTX upon cessation of CD20 expression.
3.2. Identification of rituximab response genes
by genome-wide CRISPR knockout screen in OCI-
Ly-7 cells
To screen the genome of OCI-Ly-7-Cas9, cells were
transduced with the lentiviral library (with a transduc-
tional titer of 4.7 9 107 IU/mL; Fig. S3A) at a MOI
of 0.5 (schematic overview in Fig. 2A). Whereas part
of the cells were harvested as baseline control, the
remaining cells were split in three populations that
were subjected to three different treatment schemes: (i)
mock, (ii) RTX-SEC (followed by non-CDC condi-
tions for a total of 14 days), and (iii) RTX-REC
(maintained for 21 days). The rationale was to expose
cells in the RTX-SEC group shortly to CDC condi-
tions followed by non-CDC conditions, whereas cells
in the RTX-high group were repeatedly subjected to
conditions supporting CDC (Fig. 1D). The overall dis-
tribution of sgRNA reads was determined by targeted
NGS. Plotting the cumulative frequency of log2-nor-
malized read counts from all samples showed a distor-
tion of the read distribution in the RTX-REC group,
whereas profiles for the remaining samples, including
cells surviving the RTX-SEC condition, were only
slightly skewed relative to the profile of reads derived
from sequencing of the plasmid library (Fig. 2B,
Fig. S3B). Still, all samples contained reads from
sgRNAs targeting at least 18 902 protein-coding genes,
corresponding to 99.2% of the original library. Using
MAGeCK [40], sgRNA prevalence in each of the cell
populations exposed to RTX was compared individu-
ally to mock, resulting in a ranking of each gene. By
plotting FDR against the average sgRNA log2 fold
change in read counts (Fig. 2C,D), highly ranked
genes were separated from the bulk. With a FDR cut-
off of 5%, sgRNAs targeting 44 genes were positively
enriched in RTX-SEC (Fig. 2C), whereas 47 genes, for
which sgRNAs were enriched, emerged in RTX-REC
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(Fig. 2D). A total of 20 genes scored below an FDR
of 5% in both the RTX-SEC and RTX-REC groups,
whereas a total of five genes (shown in light blue in
Fig. 2C,D) were found among the top 10 enriched
genes (indicated in Fig. 2C,D) for both conditions (ex-
haustive list of genes available in Appendix S1).
As expected from the critical role of CD20, sgRNAs
targeting MS4A1 were most prevalent in both RTX
screens, verifying that KO mutations causing resistance
to RTX were robustly pulled out from the RTX-trea-
ted cell population. Notably, at RTX-REC conditions,
the raw MS4A1 sgRNA read counts exceeded several
millions (corresponding to 41% of all reads in the
sample). Compared to RTX-SEC conditions, the
MS4A1-targeting sgRNA sequences showed a 203-fold
higher enrichment in the RTX-REC sample. Also,
within the RTX-REC group, MS4A1-targeting
sgRNAs showed a 13.93-fold higher enrichment than
sgRNAs targeting the second most enriched gene
(BLNK), whereas the two genes were similarly
enriched under RTX-SEC conditions (1.08-fold). In
addition, we identified a strong enrichment of sgRNAs
targeting CREBBP (a positive ranking of 11 and 9 at
RTX-SEC and RTX-REC conditions, respectively).
The CREBBP gene was recently reported as a regula-
tor of CD20 expression [41] and claimed to be
involved in lymphomagenesis [42]. Furthermore, our
dataset showed enrichment of sgRNAs targeting SPI1
(positive ranking of 41 and 21 at RTX-SEC and RTX-
REC conditions, respectively) as well as depletion of
sgRNAs targeting FOXO1 (a negative ranking of 166
and 154 at RTX-SEC and RTX-REC conditions,
respectively). These findings are in alignment with the
notion that CD20 is repressed by binding of FOXO1
to the MS4A1 promoter, as proposed by Scialdone
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Fig. 1. Absolute RTX resistance in OCI-Ly-7/MS4A1 KO cells. (A) Schematics of vectors used to generate OCI-Ly-7-Cas9 cells with stable
SpCas9 expression and to deliver sgRNAs. (B) Indel rates in the OCI-Ly-7-Cas9 9 days after delivery of a sgRNA targeting MS4A1. (C) Flow
cytometric determination of CD20 protein levels in OCI-Ly-7-Cas9 9 days after MS4A1 sgRNA delivery. (D) RTX drug assay with either
active or HIHS. Cells treated with 20% HIHS were grown in 50 µgmL1 RTX, whereas cells treated with 20% active HS were exposed to
a RTX concentration of 10 µgmL1. Living cells were enumerated by trypan blue exclusion following 48 h of exposure. Black dots
represent saline-treated populations, whereas red dots display RTX-treated populations. For each population of cells, living cells following
treatment were normalized by dividing the number of cells with the mean of living cells counted in the saline-treated cell population. For
each population, treatment (saline or RTX) was carried out in triplicates; mean is shown.
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showing that lower levels of SPI1 expression are
linked to decreased MS4A1 transcription [43,44],
whereas reduced levels of FOXO1 are associated with
increased MS4A1 transcription [45]. Together, these
observations not only emphasized the paramount
impact of CD20 loss on the escape from RTX-induced
CDC, but also demonstrated the validity of the screen
itself. Overall, we note that no other gene within the
B-cell genome has the substantial effect of CD20-en-
coding MS4A1 on RTX-induced CDC.
Among the remaining genes, for which sgRNAs
were enriched in the RTX-resistant cell populations,
we noted an overlap of 263 genes that were identified
among the top 1000 most enriched genes from each of
the two RTX conditions (Fig. 2C,D). We reasoned
that these 263 genes were not directly related to resis-
tance to CDC but rather reflected a group of genes
affecting the direct response to RTX under comple-
ment-depleted conditions. We explored this group of
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Fig. 2. Genome-wide CRISPR KO screening for identification of RTX response genes in OCI-Ly-7. (A) Schematic representation of screening
strategy and concept. (B) Cumulative distribution of log2-normalized sgRNA read counts for each sample. Skewing illustrates a higher
percentage of sgRNAs with a low read count. (C, D) Results from MAGeCK analysis of low and high RTX conditions compared with mock
treatment. The FDR (log10) is plotted against the log2 fold change in read counts, relative to mock, across all sgRNAs targeting each gene.
The 263 genes common for both RTX conditions (top 1000) are colored green, the top 10 genes for both RTX conditions are labeled, and
the five genes common within the top 10 are highlighted in blue. (E) GSEA performed via Enricher, showing the top five pathways from five
different databases. For each ranked pathway, the uncorrected P-value (log10) is plotted against the combined enricher score (log2). (F)
Comparison of FDR cutoff genes from both RTX samples with a BCR gene set compiled from the various pathway databases. (G–I) MS4A1,
BLNK, and BTK sgRNA read counts shown for the five samples including library plasmid preparation, baseline cells, mock-treated cell
population, and cells treated with low and high concentrations of RTX (RTX-SEC and RTX-REC). Y-axis shows log2-normalized read counts
per sgRNA.
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the 263 genes mapped mainly to pathways related to
BCR signaling (Fig. 2E), suggesting that RTX mecha-
nisms of action involve or interfere with BCR signal-
ing. When genes with a FDR cutoff of 5% were cross-
referenced with a list of BCR-related genes, we identi-
fied three genes, BLNK, BTK, and CD19 encoding
BLNK, BTK, and the B-cell surface antigen CD19,
respectively, as top-ranking BCR signaling genes iden-
tified at both RTX-SEC and RTX-REC conditions
(Fig. 2F). Lastly, we cross-referenced our candidate
genes with their scoring in mock sample (MAGeCK
analysis of mock compared to baseline) and found that
CD19-targeting sgRNAs were depleted in the mock
sample, implying that loss of CD19 had a negative
impact on growth (scoring of mock sample genes
available in Appendix S1). Hence, for MS4A1
(Fig. 2G) as well as for BLNK and BTK (Fig. 2H,I),
the library screen showed a robust enrichment of gene-
specific sgRNA sequencing reads in RTX-resistant
cells and no depletion within the mock sample. Nota-
bly, identification of BLNK (a positive ranking of 2 at
both RTX-SEC and RTX-REC conditions) and BTK
(a positive ranking of 5 and 19 at RTX-SEC and
RTX-REC conditions, respectively) points to an
important role of BCR signaling in relation to sensitiv-
ity to RTX under non-CDC conditions.
3.3. Increased resistance to rituximab in B cells
with knockout of BLNK or BTK genes
Due to the tightly connected roles of BLNK and BTK
during BCR signaling, we focused on confirming the
correlation of the response to RTX with the status of
the BLNK and BTK genes. We introduced KO muta-
tions in the original OCI-Ly-7 cell line with a series of
sgRNAs, two sgRNAs for both BLNK and BTK,
resulting in cell populations with indel rates ranging
from 60% to 80% (Fig. 3A) and shutdown of BLNK
and BTK protein synthesis (Fig. 3B). Using growth
conditions by which OCI-Ly-7 cells carrying a control
sgRNA were exposed to RTX at a concentration of
50 µgmL1 for up to 72 h, we observed the most pro-
nounced impact on cell viability after 72 h (Fig. S4).
Using these growth conditions in the presence of
HIHS, loss of BLNK or BTK protein resulted in
markedly increased tolerance to RTX relative to na€ıve
cells or cells expressing the control sgRNA (Fig. 3C).
In parallel, using all four sgRNAs, we also introduced
KO mutations in SU-DHL-5 cells, resulting in indel
rates ranging from 40% to 88% (Fig. 3D) and sup-
pressed protein levels (Fig. 3E). As in OCI-Ly-7 cells,
KO of BLNK and BTK in SU-DHL-5 cells resulted in
increased tolerance to RTX, as opposed to na€ıve cells
and cells expressing a control sgRNA, which were
both sensitive to the treatment (Fig. 3F).
To assess the impact of RTX in the context of
ABC-subtype cells lacking expression of BLNK and
BTK, we aimed at introducing MS4A1, BLNK, and
BTK KO mutations in RIVA cells, an ABC-subtype
cell line. However, whereas KO of MS4A1 was suc-
cessful, resulting in an indel rate of 81% (Fig. S5A),
introduction of indels in BLNK and BTK severely
reduced the proliferative potential of RIVA cells.
Although a smaller fraction of cells eventually became
resistant to the puromycin selection pressure, indel
rates in these cells were very low, indicating that loss
of BLNK or BTK in RIVA cells was incompatible with
in vitro growth (Fig. S5A).
3.4. Relationship between surface-expressed
CD20 levels and rituximab-induced apoptosis
As functions of BLNK and BTK could potentially
affect CD20 cell surface expression, we assessed the
CD20 levels in RTX-resistant OCI-Ly-7/BLNK-KO
and OCI-Ly-7/BTK-KO populations. CD20 levels in
these cell populations were slightly reduced relative to
sgCtrl-expressing cells, but did not deviate from na€ıve
cells (Fig. 4A). Also, MS4A1 mRNA levels in OCI-
Ly-7/BLNK-KO and OCI-Ly-7/BTK-KO cells were
unaffected (Fig. 4B), whereas MS4A1 mRNA levels
in OCI-Ly-7/MS4A1- KO cells were reduced to 50%
of the level in sgCtrl-expressing cells, most likely due
to the introduction of indels. In contrast, CD20 levels
at the surface of SU-DHL-5/BLNK-KO and SU-
DHL-5/BTK-KO cells were markedly reduced (40–
54% of the level in sgCtrl-treated cells; Fig. 4C). As
the MS4A1 mRNA levels were reduced correspond-
ingly across all KO populations to levels mimicking
the level in SU-DHL-5/MS4A1 KO cells (Fig. 4D), it
was noted that KO of BLNK as well as of BTK in
SU-DHL-5 cells resulted in the reduction of CD20
presentation on the cell surface, most likely through
mechanisms involving transcriptional and/or post-
transcriptional regulation.
To explore whether variations in cell surface expres-
sion of CD20 affected RTX-induced apoptosis in
BLNK- and BTK-deficient B cells, we set out to
reconstitute CD20 expression levels in MS4A1KO cells
by transduction of the cells with a lentiviral vector
encoding a sgMS4A1-resistant CD20 variant (Fig. S6).
OCI-Ly-7/MS4A1-KO and SU-DHL-5/MS4A1-KO
cells were therefore transduced successively (three and
two transductions, respectively), leading to gradually
increased CD20 levels spanning from 10% to 80% of
the normal level (Fig. 5A,B). To establish a population
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of SU-DHL-5 cells with the same level of CD20
expression as in SU-DHL-5/BLNK-KO and SU-DHL-
5/BTK-KO (40–50% of normal), we suppressed the
transcriptional activity of the MS4A1 locus using an
RNA-guided SpCas9-KRAB fusion variant (Fig. S6),
resulting in a CD20 expression level (50% of normal;
Fig. 5C) that mimicked the level in SU-DHL-5/BLNK-
KO and SU-DHL-5/BTK-KO cells (Fig. 4C).
We investigated the impact of RTX on B cells by
quantifying early and late apoptotic cells over time
(Fig. S7) and noticed the largest impact of RTX on
the early apoptotic fraction of cells quantified after
24 h. Hence, the percentage of early apoptotic na€ıve
OCI-Ly-7 cells after exposure to RTX for 24 h was
increased from 9.5  1.1 to 29.2  1.6% (Fig. S8).
Similar induction was seen in cells expressing the con-
trol sgRNA, whereas induction of apoptosis was
blocked as expected in OCI-Ly-7/MS4A1-KO cells due
to the absence of CD20. In cells with 10% of the nor-
mal CD20 expression, 16.5  0.9% of the cells were
early apoptotic, whereas 30.2  0.4% of the cells with
80% of normal CD20 presentation reached early
apoptosis (Fig. 5D). Upon treatment of na€ıve and con-
trol cells with RTX, the percentage of early apoptotic
cells was increased, as expected, whereas OCI-Ly-7/
MS4A1-KO cells were unaffected by the treatment
(Fig. 5D). Importantly, the basic level of apoptosis
corresponding to the level in na€ıve cells was reached
already in cells with CD20 expression levels reaching
50% of normal (Fig. 5E). In SU-DHL-5 cells, in
which the CD20 level was suppressed to 50% of nor-
mal, RTX-induced early apoptosis did not deviate
from the level in control cells (Fig. 5F,G), whereas the
capacity to induce apoptosis in cells expressing 10% of
normal CD20 levels did not differ from the capacity in


















































































































































































































Fig. 3. BLNK and BTK gene KO confers resistance to RTX in OCI-Ly-7. (A–C) and SU-DHL-5 (D–F) GCB subclass cells. (A, D) Assessment of
CRISPR KO on the genomic level by TIDE. Following two weeks of puromycin, gDNA was harvested and sequence traces from sgRNA-
treated populations were compared by TIDE with sequences from cells treated with control sgRNA, allowing frequency of indels to be
quantified. (B, E) Verification of BLNK and BTK KO assessed at the protein level by western blot. (C, F) RTX drug assay under non-CDC
conditions. Cells treated with 50 µgmL1 RTX in 20% HIHS were enumerated by trypan blue exclusion following 72 h of exposure. Black
dots represent saline-treated populations, whereas red dots display RTX-treated populations. For each population of cells, living cells
following treatment were normalized by dividing the number of cells with the mean of living cells counted in the saline-treated cell
population. For each population, treatment (saline or RTX) was carried out in triplicates; mean is shown. Dunnett’s multiple comparison test
was performed with RTX-treated sgCtrl population (*< 0.05, **< 0.005, ***< 0.0005, ****< 0.0001).
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Ly-7 and SU-DHL-5/dCas9-KRAB cells, the same
tendency was evident in the late apoptotic cells, but to
a smaller extent (Fig. S9) as was expected from our
initial quantification of late apoptotic cells appearing
after treatment with RTX (Fig. S7). In summary, our
data demonstrate that the direct effect of RTX under
non-CDC conditions correlates with CD20 levels.
However, when we considered the response toward
RTX in cells in which the CD20 expression level was
artificially engineered to mimic the levels in cells with
BLNK and BTK KO, the reduced levels of CD20
expression measured in cells carrying KO mutations of
BLNK or BTK cells did not alone explain the altered
response to RTX. We therefore conclude that sgRNAs
targeting BLNK and BTK were not solely enriched in
genome-wide screens through mechanisms involving
modulation of the CD20 expression levels.
3.5. Impairment of rituximab-directed apoptosis
in BLNK and BTK knockout populations
To further investigate the acquired resistance to RTX
in OCI-Ly-7/BLNK-KO and OCI-Ly-7/BTK-KO cells,
we determined levels of apoptosis after subjecting the
cells to RTX under non-CDC conditions. After expo-
sure of OCI-Ly-7 cells to RTX for 24 h, we did not
find indications of induced apoptosis, leading to early
apoptotic cells neither in the two BLNK KO popula-
tions nor in the two BTK KO populations (Fig. 6A).
Hence, the percentage of early apoptotic cells in OCI-
Ly-7/BLNK-KO (3.91  0.1% for sg1-BLNK) and
BTK KO (4.01  0.4% for sg1-BTK) mimicked the
level in OCI-Ly-7/MS4A1-KO (3.24  0.1%), which
was substantially lower than the level reached in con-


























































































































































Fig. 4. Cell type-specific impact on CD20 expression levels in GCB-subtype cells OCI-Ly-7. (A, B) and SU-DHL-5 (C, D) cells with KO of
BLNK and BTK. (A, C) CD20 expression levels assessed by flow cytometry. Three separate samples from each population were prepared
for flow. Illustrated ratios represent median fluorescent intensity of living cells relative to na€ıve expression level; shown is mean. (B, D)
CD20 mRNA levels determined by qPCR. Three samples from each population were harvested, and for each, PCR was performed in
duplicates for each sample. CD20 relative levels among samples were normalized to levels in na€ıve cells; shown is mean. Ct values were
analyzed based on the standard curve method, and resulting relative values were used for Dunnett’s multiple comparison test against the
sgCtrl population (*< 0.05, **< 0.005, ***< 0.0005, ****< 0.0001).
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the same trend was evident in the fraction of late
apoptotic cells after RTX treatment (Fig. S10A).
Additionally, for OCI-Ly-7 we found the same effect
on the apoptotic response after 48 and 72 h (Fig. S11).
In SU-DHL-5 cells, the percentage of early apoptotic
cells increased upon exposure to the drug for 48 h,
although the basic level of the annexin V stain was
higher in these cells (Fig. 6C). Notably, relative to
sgRNA control cells, SU-DHL-5/MS4A1-KO cells did
not undergo induced apoptosis upon exposure to RTX
(Fig. 6D). Similarly, treatment of SU-DHL-5/BLNK-
KO and SU-DHL-5/BTK-KO cells with RTX did not
increase the early apoptotic levels beyond the levels
observed in the absence of RTX (Fig. 6C,D), suggest-
ing that the lack of BLNK and BTK rendered the cells
unable to undergo programmed cell death induced by
RTX. A similar lack of response was evident in the
fraction of late apoptotic cells after RTX treatment
(Fig. S10B). Altogether, our findings demonstrate that
BCR signaling through BTK and BLNK is essential
for RTX-induced signaling and subsequent apoptosis
in GCB-subtype DLBCL cells.
4. Discussion
B-cell proliferation and differentiation is driven by
multibranched intracellular signaling cascades propa-
gating through BCR antigen recognition. As a key reg-
ulator of cell growth, BCR signaling is vulnerable for
irregularities driving outgrowth of malignant B cells,
as evident in DLBCL [46,47]. In ABC-subtype
DLBCL, malignancy is driven by antigen-induced
BCR activation [48], whereas signaling through BCR
in GCB-subtype DLBCL is suggested to occur inde-
pendently of antigen recognition through ‘tonic’ mech-
anisms [49]. Despite the key function of BCR in
triggering proliferative growth signals that may
potentially be malignant, signaling through BCR may
also be crucial in attempts to treat B-cell cancer with
R-CHOP. Hence, it is now generally accepted that
intracellular signals driven by the BCR are directly
affected by the binding of RTX to CD20 with direct
effects on cell growth and survival [18,19,50]. Here, we
set out to screen the genome of OCI-Ly-7, a GCB-sub-
type B-cell line, for genes related to resistance toward
RTX using a lentivirus-based genome-wide CRISPR/
Cas9 screening approach. By applying different RTX
selection modalities to a large heterologous population
of cells, with each cell carrying CRISPR-induced gene-
disruptive indels in a single gene, we identified genes
with functions that support sensitivity to RTX. Under
conditions where the library-treated population of
OCI-Ly7 cells was exposed to RTX, we consistently
found sgRNAs targeting the MS4A1 gene as predomi-
nantly enriched, supporting that CD20 is essential for
the cytotoxic impact of RTX. In addition to the
expected identification of MS4A1, the rankings of
CREBBP, SPI1, and FOXO1 within our screening
data support the notion that CREBBP and SPI1 are
involved in promoting CD20 expression and FOXO1
repression by binding to the MS4A1 promoter, a
model proposed by Scialdone and coworkers [41]. Pre-
viously, MS4A1 expression has been investigated by
shRNA-based screening of the genome [51] showing
that SPI1 was also in this study linked to reduced
MS4A1 expression. Overall, such observations support
the validity of our approach and may potentially sug-
gest that several of the remaining identified genes play
roles in modulating MS4A1 expression.
In OCI-Ly-7 and SU-DHL-5, both GCB cell lines,
we successfully validated that KO of the BLNK and
BTK genes resulted in induced resistance to RTX,
leading to increased cell viability. Such resistance was
more pronounced in OCI-Ly-7 as compared to SU-
Fig. 5. RTX response in relation to CD20 surface levels. (A, B) Surface expression levels of CD20 in OCI-Ly-7 (A) and SU-DHL-5 (B)
following multiple lentiviral transductions with LV/PGK-CD20; three separate samples from each population were prepared for flow.
Illustrated ratios represent median fluorescent intensity relative to na€ıve; shown is mean. (C) CD20 surface expression in SU-DHL-5/KRAB
cells transduced with either control sgRNA or sgRNAs targeting MS4A1. CD20 expression was quantified by flow cytometry; from each
population, triplicates were prepared for flow. Illustrated ratios represent median fluorescent intensity relative to the untreated population;
shown is mean. (D) Representative plots from flow cytometric assessment of apoptosis in OCI-Ly-7 CD20-reconstituted populations treated
with 50 µgmL1 RTX and 20% HIHS for 24 h. (E) Summarized percentage of early apoptotic cells of OCI-Ly-7 populations with
reconstituted CD20 levels. Black dots represent the saline-treated populations, whereas red dots display RTX-treated populations. Dunnett’s
multiple comparison test was performed with RTX-treated MS4A1-sg1 population. (F) Representative plots from flow cytometric
assessment of apoptosis in SU-DHL-5/KRAB MS4A1 inhibition populations following 48 h of treatment with 50 µgmL1 RTX and 20%
HIHS. (G) Summarized percentage of early apoptotic cells of SU-DHL-5/KRAB populations with suppressed expression of the MS4A1 gene.
Black dots represent saline-treated populations, whereas red dots display RTX-treated populations. For each population, treatments (saline
or RTX) were carried out in triplicates; mean is shown. Dunnett’s multiple comparison test was performed with RTX-treated sgCtrl
population (*< 0.05, **< 0.005, ***< 0.0005, ****< 0.0001).
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DHL-5, an observation possibly explained by a differ-
ence in the intrinsic sensitivity toward RTX under
non-CDC conditions. This is in line with previous
studies reporting that OCI-Ly-7 cells are more sensi-
tive toward RTX under non-CDC conditions than
SU-DHL-5 cells [52]. To assess the impact of lost
BLNK and BTK gene function in the ABC context, we
made attempts to disrupt these genes in RIVA, an
ABC cell line. However, treatment of RIVA cells with
sgRNAs targeting BLNK and BTK severely hindered
proliferation of RIVA cells, and the surviving popula-
tion of cells was enriched for cells without BLNK and
BTK KO mutations. This supports previous findings
showing that growth of ABC subclass cells depends on
BCR signaling feeding into a constant hyperactivation
of NF-ΚB signaling [48]. Notably, this also indicates
that the unique involvement of BLNK and BTK in
shaping the resistance to RTX, without being crucial
for cell growth, could potentially apply exclusively to
GCB-subtype cells.
Due to the well-established function of BLNK and
BTK proteins as key players in BCR signaling path-
ways, we explored our screen data with focus on other
core BCR genes, acting upstream of BLNK and BTK.
Notably, neither CD79A nor CD79B, encoding pro-
teins which both which act immediately downstream
from the BCR [53], were among the top-ranked genes
in the screen (a positive ranking of 6953 and 18 187 of
CD79A and CD79B, respectively, in the RTX-SEC
condition) or in the mock sample (a positive ranking
of 15 273 and 18 843 of CD79A and CD79B, respec-
tively). The low ranking of the CD79A and CD79B
genes is in line with the low ranking of CD19 (a nega-
tive ranking of 829 in the mock sample) and could
indicate that KO of these as well as other key BCR
signaling genes directly affected cell growth or survival
under normal conditions. These findings are in accor-
dance with recent findings showing that GCB cell lines
depend on ‘tonic’ BCR-induced signaling through
PI3K/AKT [49]. Importantly, such tonic BCR signal-
ing in GCB-subtype cells seems to occur independently
of the BLNK and BTK proteins, whereas cessation of
BLNK and BTK gene expression interferes with signal-
ing pathways that are normally affiliated with RTX-
induced intracellular signals leading to constrained cell
growth or apoptosis.
Considering the specificity of RTX for CD20, the
impact of the BLNK and BTK genes on RTX resis-
tance suggests that stimulation of CD20 feeds into
BCR signaling, a claim which is also supported by
recent publications linking RTX response in chronic
lymphocytic leukemia to BCR signal-proficient cell
populations [54] and studies of RTX-induced BCR
signaling in follicular lymphoma cell lines [21]. As
expected, we found that cessation of CD20 surface
expression led to complete RTX tolerance both in
relation to CDC and direct intracellular effects. CD20
is involved in calcium-related signaling and plays an
important role in T-cell independent activation of B
cells [55], which could explain its close relations to the
BCR. Also, previous reports have shown reduced
expression of BCR and decreased BCR signaling in
CD20-/- mice [56]. This connection is supported by
association between expression of the MS4A1 gene
and expression of several BCR-related genes in patient
samples [57] and evidence of physical association with
the BCR [58]. The direct association between CD20
and BCR has previously been linked to aggregation
of membrane lipid rafts [59,60], a theory supported by
the recent resolution crystal structure of RTX bound
to CD20, demonstrating CD20 super assemblies in the
cell membrane [61]. In addition to a potential impact
of CD20 on BCR signaling, the exposure of cells to
antibodies directed at CD20 has previously been
reported to elicit changes in BCR signaling. For
instance, CD20 stimulation was shown to induce
phosphorylation of PLCG2 (gene positively ranked 57
and 111 at RTX-SEC and RTX-REC conditions,
respectively), a protein in direct interaction with
BLNK and BTK as part of BCR signaling [62]. Fur-
thermore, stimulation by RTX and obinutuzumab (a
third-generation anti-CD20 antibody) was compared
by global phosphoproteomics, revealing that phospho-
rylation of several proteins involved in BCR signaling
was induced by both antibodies [50]. Of particular
interest, a direct association of CD20 with the BCR
and subsequent phosphorylation of BLNK following
stimulation of CD20 has been linked to calcium
Fig. 6. Absence of RTX-induced apoptosis in BLNK and BTK KO OCI-Ly-7. (A, B) and SU-DHL-5 cells (C, D). (A, C) RTX apoptosis assay with
non-CDC conditions; representative samples are shown. Cells were treated with 50 µgmL1 RTX in 20% HIHS. Levels of apoptosis were
determined by annexin V and live/dead staining. OCI-Ly-7 cells were exposed to RTX for 24 h and SU-DHL-5 cells for 48 h. (B, D)
Summarized percentage of early apoptotic cells. Black dots represent saline-treated populations, whereas red dots display RTX-treated
populations. For each population, treatments (saline or RTX) were carried out in triplicates; mean is shown. Dunnett’s multiple comparison
test was performed with RTX-treated sgCtrl population (***< 0.0005, ****< 0.0001).
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signaling [17]. Calcium signaling following treatment
with RTX has previously been connected to apopto-
sis, evident by the effects of inhibiting store-operated
calcium entry [16]. Also, studies have linked treatment
with RTX to activation of BCR-dependent induction
of apoptosis. Specifically, apoptosis induced by CD20
stimulation was shown to be mediated through cas-
pase-3 [18,19]. As expected, we observed an increase
in apoptotic levels in unmodified B-cell lines exposed
to RTX. In contrast, MS4A1 KO populations showed
no induction of apoptosis. Notably, KO of BLNK
and BTK resulted in the exact same phenotype ren-
dering the GCB-type B-cell lines resistant to RTX-in-
duced apoptosis. Collectively, our data demonstrate
the action of RTX through BCR signaling leads to
apoptosis.
Despite shared pathways between CD20- and BCR-
directed intracellular signaling, CD20 remains the gate-
way to RTX-mediated effects. As such, resistance
toward RTX-induced CDC has previously been inves-
tigated in relation to MS4A1 expression level [52,63–
65]. Therefore, we assessed the MS4A1 expression
levels in OCI-Ly-7 and SU-DHL-5 cells following
BLNK and BTK KO. Expression of CD20 was only
vaguely reduced in OCI-Ly-7 cells upon BLNK and
BTK KO, whereas lack of BLNK or BTK led to a
marked reduction of CD20 levels in SU-DHL-5 cells.
Our observations are in line with previous studies
showing that interference with BCR signaling, by
treatment with SRC family kinase inhibitors and BTK
inhibitors, leads to reduced MS4A1 expression [66–69].
By generating a range of cell lines expressing CD20 at
levels ranging from 5% to 80% of the level in na€ıve
cells, we observed a correlation between the level of
CD20 and the effect of RTX under non-CDC condi-
tions, as has previously been observed [21]. However, at
CD20 expression levels comparable to those observed in
BLNK KO and BTK KO cells, we observed no differ-
ence in apoptosis induction (Fig. 5E,G). Combined with
the fact that OCI-Ly-7 cells show the least reduction in
CD20 levels and yet acquire the most pronounced RTX
resistance following loss of BLNK and BTK, altered
CD20 levels due to the lack of BLNK and BTK did not
alone explain the acquired resistance, suggesting that
RTX-induced apoptosis was mediated by intracellular
signaling through BLNK and BTK.
5. Conclusions
In combination with previous studies on the effect of
BTK inhibitors on RTX sensitivity [66–69], our find-
ings could potentially point to conflicting consequences
related to the use of BTK or other BCR inhibitors to
RTX-containing regimes. One may ask whether inhibi-
tion of BTK is likely to increase B-cell resistance to
RTX? As illustrated by the differences among GCB
and ABC subtypes in relation to dependency of BLNK
and BTK, this potential contraindication may prove
also to be subtype-specific. Analysis of such differences
between GCB and ABC subtypes could potentially
give insight to explain why attempts to treat DLBCL
patients, specifically based on GCB and ABC sub-
types, with novel compounds have in large failed.
In conclusion, our data support that CD20-depen-
dent RTX-induced signaling under non-CDC condi-
tions feeds into BCR signaling and reveal a GCB
subclass-specific gain of RTX resistance caused by
both complete shutdown of RTX-induced apoptosis
pathways and reduced CD20 expression following loss
of BLNK and BTK.
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Fig. S1. Efficient lentiviral transfer to malignant B-
cells at low MOI. (A) Schematic representation of vec-
tors pCCL/PGK-eGFP and pLentiCRISPRv2, the lat-
ter which was used to produce KO cell lines. (B)
Transductional titers of LV/PGK-eGFP and LV/
CRISPRv2 in OCI-Ly-7 cells. Copy numbers following
transduction were determined by qPCR; number of
transducing units per milliliter is displayed. Three sep-
arate transductions were performed, and qPCR were
performed in technical duplicates; shown is mean. (C)
Median enhanced green fluorescent protein (eGFP) flu-
orescence in OCI-Ly-7 and SU-DHL-5 cells following
transduction with different doses of LV/PGK-eGFP.
MOI estimates are based on qPCR. (D) Percentage of
eGFP-positive OCI-Ly-7 and SU-DHL-5 cells follow-
ing transduction with different doses of LV/PGK-
eGFP. MOI estimates are based on qPCR; three sepa-
rate samples from each population were prepared for
flow. Mean is shown.
Fig. S2. Lentiviral gene delivery to B-cell lines does
not affect CD20 surface levels. CD20 surface expres-
sion in OCI-Ly-7 (A) and SU-DHL-5 (B) populations
transduced with different lentiviral constructs. Three
transductions per dose were performed. Illustrated
ratio represent median CD20 fluorescent intensity rela-
tive to na€ıve population; shown is mean. (C) Gating
strategy for flow cytometric assessment of CD20
expression levels.
Fig. S3. CRISPR library delivery and representation.
(A) Transduction titer of lentiviral preparation used to
deliver the Gecko v2 CRISPR library. Copy numbers
following transduction were determined by qPCR;
number of transducing units per milliliter is displayed.
Three separate transductions were performed, and
qPCR were performed in technical duplicates. Shown
is mean. (B) Violin plots of sgRNA read counts across
all samples; log2-normalized read counts have been
plotted.
Fig. S4. Response to rituximab dependent on exposure
time. Rituximab drug assay with non-CDC conditions
in OCI-Ly-7 cells expressing control sgRNA. Cells
were treated with 50 µgmL1 rituximab in 20% HIHS
and counted using trypan-blue exclusion following 24,
48 and 72 h of incubation. Black dots represent saline-
treated populations, whereas red dots display ritux-
imab-treated populations. For each population of cells,
living cells following treatment was normalized by
dividing the number of cells with the mean of living
cells counted in the saline-treated cell population. For
each population, treatment (saline or rituximab) was
carried out in triplicates; mean is shown.
Fig. S5. Failure to KO BLNK and BTK genes in
ABC-subclass cell line RIVA. (A) TIDE analysis of
MS4A1, BLNK and BTK genes in RIVA cells from
one of the attempts. Attempts were made to KO
BLNK and BTK with two individual sgRNAs per gene
along with successful KO of MS4A1.
Fig. S6. Modulation of CD20 levels by successive
transductions and CRISPR-based inhibition of
MS4A1 transcription. (A) Schematic representation of
pCCL/PGK-MS4A1 with details on silent mutations
introduced to abolish the sgRNA target site and pLX-
331-KRAB-Cas9 (used to produce SU-DHL-5 cells
with stable expression of KRAB-fused hSpCas9). Per-
centage of OCI-Ly-7 CD20 positive cells (B) and
CD20 median fluorescent intensity (C) following trans-
duction with different doses of LV/PGK-CD20. Per-
centage of SU-DHL-5 CD20 positive cells (D) and
CD20 median fluorescent intensity (E) following trans-
duction with different doses of LV/PGK-CD20. Three
separate samples from each population were prepared
for flow. Illustrated ratios represent median fluorescent
intensity relative to na€ıve cells, shown is mean and.
Fig. S7. Level of rituximab-induced apoptosis depends
on exposure time. Cells were treated with 50 µgmL1
rituximab in 20% HIHS for 24, 48, and 72 h. Apop-
totic levels were determined by annexin V and live/
dead staining. Early and late apoptotic levels in OCI-
Ly-7 cells expressing control sgRNA (A, B) and in
SU-DHL-5 cells expressing control sgRNA (C, D).
Summarized percentage of apoptotic cells. Black dots
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represent saline-treated populations, whereas red dots
display rituximab-treated populations. For each popu-
lation, treatment (saline or rituximab) were carried out
in triplicates; mean is shown. (E) Gating strategy for
flow cytometric detection of apoptotic levels.
Fig. S8. Complete blockage of rituximab-induced
apoptosis in OCI-Ly7 cells following MS4A1 KO. (A)
Representative plots of apoptosis assay in OCI-Ly-7
cells. Cells were treated with 50 µgmL1 rituximab in
20% HIHS for 24 h. Apoptotic levels were determined
by annexin V and live/dead staining. (B) Summarized
percentage of early apoptotic cells. Black dots repre-
sent saline-treated populations, whereas red dots dis-
play rituximab-treated populations. For each
population, treatment (saline or rituximab) were car-
ried out in triplicates; mean is shown.
Fig. S9. Percentage of late apoptotic cells at varying
levels of CD20 cells following exposure to rituximab.
(A) OCI-Ly-7 and (B) SU-DHL-5/dCas9-KRAB.
Black dots represent saline-treated populations,
whereas red dots display rituximab-treated popula-
tions. For each population, treatment (saline or ritux-
imab) were carried out in triplicates; mean is shown.
Fig. S10. Percentage of late apoptotic cells following
24 h of rituximab. (A) OCI-Ly-7 and (B) SU-DHL-
5. Black dots represent saline-treated populations,
whereas red dots display rituximab-treated popula-
tions. For each population, treatment (saline or
rituximab) were carried out in triplicates; mean is
shown.
Fig. S11. Apoptotic levels in OCI-Ly-7 cells following
longer exposure to rituximab. OCI-Ly-7 cells were
treated with 50 µgmL1 rituximab in 20% HIHS for
48 h (A, B) or 72 h (C, D). Apoptotic levels were
determined by annexin V and live/dead staining. For
each population, three treatments (saline or rituximab)
were carried out. (A, C) summarized percentage of
early apoptotic cells, (B, D) summarized percentage of
late apoptotic cells. Black dots correspond to saline-
treated populations, whereas red dots display ritux-
imab treated populations. For each population, treat-
ment (saline or rituximab) were carried out in
triplicates; mean is shown.
Appendix S1. CRISPR screen data. Analyzed data
from genome-wide CRISPR screen.
Appendix S2. BCR gene set and oligos. Gene set of
263 commonly enriched genes submitted for EnrichR
analysis and sgRNA and TIDE primer sequences.
Appendix S3. Raw data for all figures. Excel spread-
sheet with data used for calculations and plotting
related to each figure.
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